Profen and Gastrointestinal hypermotility - a phase IV clinical study of FDA data

Summary:

Gastrointestinal hypermotility is reported as a side effect among people who take Profen (ibuprofen), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Escitalopram, and have Cataplexy.

The phase IV clinical study analyzes which people have Gastrointestinal hypermotility when taking Profen. It is created by eHealthMe based on reports of 239,319 people who have side effects when taking Profen from the FDA, and is updated regularly.

What is Profen?

Profen has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 245,311 Profen users. Check the latest studies of Profen.

What is Gastrointestinal hypermotility?

Gastrointestinal hypermotility (over activity of the intestinal tract) is found to be associated with 72 drugs and 199 conditions by eHealthMe. Check the latest studies of Gastrointestinal hypermotility.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

239,319 people reported to have side effects when taking Profen.
Among them, 19 people (0.01%) have Gastrointestinal hypermotility.

Could Profen cause Gastrointestinal hypermotility?

Among these 19 people:

How long have people been on Profen when they have Gastrointestinal hypermotility? *

What is the gender of people who have Gastrointestinal hypermotility when taking Profen? *

female: 22.22 %
male: 77.78 %

What is the age of people who have Gastrointestinal hypermotility when taking Profen? *

What are other drugs people take besides Profen? *

What are other side effects people have besides Gastrointestinal hypermotility? *

Diarrhea: 13 people, 68.42%
Loss Of Consciousness: 12 people, 63.16%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 12 people, 63.16%
Poisoning: 12 people, 63.16%
Electrocardiogram Qt Prolonged: 12 people, 63.16%
Electrocardiogram Qt Shortened: 11 people, 57.89%
Sleep Apnea Syndrome: 3 people, 15.79%
Exfoliative Rash (scaly red generalized skin rash): 3 people, 15.79%
Stomatitis (inflammation of mucous membrane of mouth): 3 people, 15.79%
Rash Erythematous (redness of the skin): 3 people, 15.79%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 15.79%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 15.79%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 10.53%
Oral Pain: 2 people, 10.53%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 10.53%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 5.26%
Indigestion: 1 person, 5.26%
Hepatitis C: 1 person, 5.26%
Diarrhea: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Profen and have Gastrointestinal hypermotility?

- Check whether Gastrointestinal hypermotility is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Profen:

Profen (245,311 reports)

Browse all side effects of Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal hypermotility:

Gastrointestinal hypermotility (72 drugs)

Browse all the conditions that are associated with Gastrointestinal hypermotility:

Gastrointestinal hypermotility (199 conditions)

Related publications that referenced our studies

Moslim MA, Sodeman TC, Nawras AT, "A Case of Suggested Ibuprofen-Induced Acute Pancreatitis", American journal of therapeutics, 2016 Nov .
Moslim MA, Sodeman TC, Nawras AT, "A Case of Suggested Ibuprofen-Induced Acute Pancreatitis", American journal of therapeutics, 2016 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on ibuprofen (the active ingredients of Profen) and Profen (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.